Total Funding
66
61
Total FundingPost-IPO Equity raised
Growth Score
-6 pts
Heat Score
-11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
40393
Revance is a biotechnology company focusing on aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences.
Acquired by 
Crown Laboratories
Todd Gross: Vice President, Biostatistics & Data ManagementPast Role: Kythera Biopharmaceuticals, Vice President, Clinical Development, Biostatistics and Data Management- David A. Hollander: Chief Medical OfficerPast Role: Aerie Pharmaceuticals, Chief R&D Officer
Crown Laboratories
About the Company
Revance Therapeutics is a biopharmaceutical company, engages in developing and commercializing products and treatments in dermatology and aesthetic medicines. Its products include RT001, a physician-applied topical botulinum toxin type A (BoNT-A) for cosmetic, hyperhidrosis, and dermatologic indications. The company was formerly known as Essentia
Biosystems.
